PTGX Q4 2023 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M

Gross Profit

$60M100.0% margin

Operating Income

$23M38.4% margin

Net Income

$27M45.6% margin

EPS (Diluted)

$0.44

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$17M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$358M

Total Liabilities

$21M

Stockholders' Equity

$337M

Cash & Equivalents

$187M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$0	—
Gross Profit	$60M	$0	—
Operating Income	$23M	-$37M	+163.1%
Net Income	$27M	-$34M	+179.9%